Clinical Trial Update: CML Treated With Bosutinib After Relapse [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bosutinib for chronic myeloid leukemia after relapse has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloblastic Leukemia

Drugs mentioned

• Bosutinib (bosutinib)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Chronic Myeloblastic Leukaemia | Phase 2 | Status: COMPLETED